Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
How Big Data Transforms Reactive Drug Safety to Proactive Pharmacovigilance
Posted on March 7th, 2019 by Marnix Wieffer in Pharma R&D
Adverse drug reactions can be costly and cost is just the tip of the iceberg. This is highlighted by an FDA website which cites troubling statistics such as the 100k deaths and over 2 million serious adverse drug reactions experienced each year…
(more…)Are Drug-Drug Interactions Today’s Biggest Health Threat?
Posted on October 16th, 2018 by Christy J. Wilson in Pharma R&D
The use of prescription medicines is sharply on the rise. Over the past decade, the number of adults taking over-the-counter medicines has sunk, while the number of prescription drug users has increased by more than 30 percent. (more…)
In pharmacovigilance, effective search strings are key
Posted on February 9th, 2018 by Xuanyan Xu in Pharmacovigilance
A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. (more…)
Why a reliable FAERS searching capability is essential for pharma companies
Posted on October 27th, 2017 by Sherry Winter in Pharmacovigilance
In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” (more…)
